Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by William Ledger
AI Assistant for Real Estate Investors — Deal Math, Seller Scripts & Lead Workflow (C
Built this for fellow investors after noticing every AI prompt pack out there is written for agents — listing descriptions, social media content, none of it useful if you're a wholesaler, landlord, or flipper. This is different.
Premature ovarian failure
Summary Cessation of menses for more than 1 year before 40 years of age secondary to loss of ovarian function. Symptoms include amenorrhea and symptoms of hypoestrogenism such as hot flashes, sleep disturbance, irritability, and vaginal dryness. Usually results in infertility, although spontaneous ovulation and pregnancy can occur rarely after its diagnosis. Differential diagnosis includes genetic/chromosomal abnormalities, autoimmune disorders, infections, and toxic and idiopathic causes.
Provision of Fertility Preservation for Young Women with Early-Stage Breast Cancer
1. Introduction Breast cancer is the most common cancer in women worldwide with an estimated 2.3 million new cases worldwide in 2020 [1] . Traditionally considered as a disease of post-menopausal women, the incidence among pre-menopausal women is increasing with around 10% of newly diagnosed breast cancer among women less than 40 years old [2] . The management of breast cancer in young women brings unique challenges.
Four‐dimensional ultrasound biometry following botulinum toxin type A injection to the pelvic floor
CLINICAL ARTICLE Erin M. Nesbitt-Hawes BMed(Hons), FRANZCOG, PhD, Corresponding Author e.nesbitt-hawes@unsw.edu.au orcid.org/0000-0002-4454-0653 School of Women's and Children's Health, UNSW, Sydney, Australia Department of Gynaecology, Royal Hospital for Women, Randwick, Australia Correspondence Erin Nesbitt-Hawes, Department of Gynaecology, Royal Hospital for Women, Randwick, NSW 2031, Australia.
Preimplantation genetic screening should be used in all in vitro fertilisation cycles in women over the age of 35 years: AGAINST: Pre‐implantation genetic screening should not be used in all IVF cycles in women over the age of 35 years - Ledger - 2019 - B
BJOG Debate William Ledger Corresponding Author E-mail address: w.ledger@unsw.edu.au Faculty of Medicine, School of Women's and Children's Health, UNSW Medicine, Sydney, New South Wales, Australia Search for more papers by this author There is little doubt that the appropriate use of pre‐implantation genetic testing can be beneficial.
In-vitro regulation of primordial follicle activation: challenges for fertility preservation strategies
AMH or Müllerian inhibitory substance (MIS) is a member of the TGF-? superfamily. AMH is secreted by growing pre-antral and small antral follicles and is thought to inhibit primordial follicle activation and pre-antral development (Campbell et al, 2012, Carlsson et al, 2006, Cushman et al, 2002, Durlinger et al, 2002, Durlinger et al, 1999, Gigli et al, 2005, Nilsson et al, 2007, Nilsson et al, 2011, Visser, Themmen, 2005).
BJOG: An International Journal of Obstetrics & Gynaecology
The HFEA has come a long way since its inception in 1990. Public and professional concern was initially focused on the many ethical challenges presented by the new technologies used in ART, and in particular the need for consideration of the welfare of children that may be born after their use.
Anti-Müllerian hormone kinetics in pregnancy and post-partum: a systematic review
Eight studies fulfilled the inclusion criteria for the systematic review. Methodological and clinical characteristics of the eligible studies are listed in Table?2, Table?3. The studies were published between 2005 and 2015 and varied in size from 60 to 554 patients, with a total of 1719 patients across the studies. All data used in this systematic review were from pregnant women at various stages of gestation.
Evidence-Based Lifestyle and Pharmacological Management of Infertility in Women with Polycystic Ovary Syndrome
Ranking: 2015 SJR (SCImago Journal Rank) Score: 0.691 | 478/1779 Medicine (miscellaneous) (Scopus®) | Indexed in MEDLINE/PubMed Evidence-Based Lifestyle and Pharmacological Management of Infertility in Women with Polycystic Ovary Syndrome Michael F Costello*,1,2 William L Ledger*,1,2 1School of Women's & Children's Health, Division of Obstetrics & Gynaecology, University of New South Wales, Level 1 Women's Health Institute, Royal Hospital for Women, Locked Bag 2000, Randwick, Sydney, NSW...
Targeted Therapy in Ovarian Cancer
Ranking: 2015 SJR (SCImago Journal Rank) Score: 0.691 | 478/1779 Medicine (miscellaneous) (Scopus®) | Indexed in MEDLINE/PubMed Targeted Therapy in Ovarian Cancer Hui Jun Lim1 William Ledger2,* 1Faculty of Medicine, University of New South Wales, Australia 2School of Women's & Children's Health, University of New South Wales, Sydney 203‘, New South Wales, Australia ?*Author for correspondence: w.ledger{at}unsw.edu.au Abstract Among female-specific cancers worldwide, ovarian cancer is the...
Anti-Müllerian Hormone is All You Need: An Assisted Reproductive Technology Perspective in Diagnosing Polycystic Ovary Syndrome
Anti-Müllerian Hormone is All You Need: An Assisted Reproductive Technology Perspective in Diagnosing Polycystic Ovary Syndrome
Emerging infertility treatment could be a less invasive and cheaper alternative to IVF
In-vitro fertilisation (IVF) has helped infertile couples start families for more than 35 years. But while the technology has evolved, it remains an expensive, invasive process that can have significant side-effects. Our team of Australian and Belgian medical scientists have developed an infertility treatment that could result in a simpler, cheaper infertility treatment using fewer drugs. Our findings will be presented today at the Annual Scientific Meeting of the Society for Reproductive Biology.
Random start or emergency IVF/in vitro maturation: a new rapid approach to fertility preservation
Random start or emergency IVF/in vitro maturation: a new rapid approach to fertility preservation There is a need to develop rapid protocols for ovarian stimulation for women who wish to preserve their fertility following diagnosis of cancer. Conventional gonadotropin stimulation protocols are lengthy and are delayed until the start of the next menstrual period, potentially compromising cancer treatments.
Targeted therapy in ovarian cancer
Among female-specific cancers worldwide, ovarian cancer is the leading cause of death from gynecologic malignancy in the western world. Despite radical surgery and initial high response rates to first-line chemotherapy, up to 70% of patients experience relapses with a median progression-free survival of 12–18 months. There remains an urgent need for novel targeted therapies to improve clinical outcomes in ovarian cancer.
Improving fertility preservation for girls and women by coupling oocyte in vitro maturation with existing strategies
Citation Posted online on May 18, 2016. CommentaryImproving fertility preservation for girls and women by coupling oocyte in vitro maturation with existing strategiesXiaoqian Wang1, Debra A Gook2,3, Kirsty A Walters4, Antoinette Anazodo4,5,6, William L Ledger4 & Robert B Gilchrist*,4
Anti-Müllerian hormone is all you need: an assisted reproductive technology perspective in diagnosing polycystic ovary syndrome
Citation Posted online on May 11, 2016. EditorialAnti-Müllerian hormone is all you need: an assisted reproductive technology perspective in diagnosing polycystic ovary syndromeKate McCullough1 & William Ledger*,2
Anti-Müllerian Hormone is All You Need: An Assisted Reproductive Technology Perspective in Diagnosing Polycystic Ovary Syndrome
“…levels of anti-Müllerian hormone alone are strongly related to polycystic ovary syndrome as a cause of anovulation and can also give insight into a woman's potential to respond to fertility treatment.” Many different groups of medical specialists provide care to women with polycystic ovary syndrome (PCOS). These include general practitioners, endocrinologists, gynecologists and fertility specialists.
Random Start or Emergency IVF/in vitro Maturation: A New Rapid Approach to Fertility Preservation
This study was supported by research grants from the Canadian Institutes of Health Research; Canadian Foundation for Women's Health; Establishment Grant from the University of Saskatchewan; the National Health and Medical Research Council of Australia (Program Grant # 494802 and Research Fellowships, DM Roberston #169201, RB Gilchrist #441023210); and the Victorian Government's Operational Infrastructure Support Program.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with William
Contact William, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack